Newest
Business
-
NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 14th + KARMAN POPS DOUBLE DIGIT IPO
NEW YORK,Feb. 14,2025-- The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today\'s NYSE Pre-market update for market insight
02-17
Details -
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
SUZHOU,China,Feb. 13,2025-- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 bi
02-14
Details -
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
SEOUL,South Korea,Feb. 13,2025-- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement w
02-14
Details -
Year of the Snake Celebrations Bring Lively Festivities to Cangzhou
CANGZHOU,China,Feb. 13,2025-- A news report from xinhuanet: The Year of the Snake ushers in an energetic Spring Festival in Cangzhou,Hebei Province. Locals and tourists alike are reveling in the festi
02-14
Details -
AI is turbocharging media production and democratizing creativity, but challenges persist for the industry, reveals new MIT Technology Review Insights research report
Digital media standards underlie every advance CAMBRIDGE,Mass.,Feb. 13,2025-- A new report byMIT Technology Review Insights explores how emerging tech is remaking the media and entertainment industri
02-14
Details -
enreap Earns 2025 Great Place To Work Certification™
PUNE,India,Feb. 13,2025-- enreapis proud to be Certified™ by Great Place To Work® for the third year in a row. The prestigious award is based entirely on what current employees say about their ex
02-14
Details -
Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial.
02-14
Details -
Namibox, Tencent, and Sichuan Education Press Forge Strategic Partnership to Develop Innovative AI-Powered Learning Solutions
SHANGHAI,Feb. 13,2025-- Jinxin Technology Holding Company (the "Company") (Nasdaq: NAMI),an innovative provider of digital-content products and services in China,today announced an in-depth
02-14
Details -
TVU Networks Pioneers Breakthrough Coverage of World's Largest Religious Gathering in India
TVU Networks provided professional broadcasting solutions to cover one of the world\'s largest religious gatherings.
02-13
Details -
Vipshop to Announce Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025
GUANGZHOU,China,Feb. 11,2025--Vipshop Holdings Limited (NYSE: VIPS),a leading online discount retailer for brands in China ("Vipshop" or the "Company"),today announced that it plan
02-13
Details